ADIPOQ and metabolic dysfunction-associated steatotic liver disease: We posit that the early activation of the antisteatogenic adiponectin-LKB1-AMPK-FOXO-signaling axis effectively protects the CHIP−/−-liver from aggravated NAFLD/NASH-manifestations.